Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: In the ICARIA-MM trial, isatuximab plus pomalidomide-dexamethasone (Pd) significantly prolonged progression-free survival, compared with Pd alone, in patients with relapsed or refractory multiple myeloma (RRMM), including those with gain or amplification of chromosome 1q, region 2, band 1 (1q21+).
Case Presentation: We describe a 62-year-old Japanese man with 1q21+ RRMM, previously treated with three lines of therapy, who had a rapid and durable response to isatuximab-Pd. After the first isatuximab-Pd cycle, he had a complete response or better, which was maintained throughout 54 cycles (4.25 years). Isatuximab-Pd was generally well tolerated. The only serious adverse event was grade 3 cataracts.
Conclusion: Our case shows that isatuximab-Pd is capable of inducing an enduring response in a patient with 1q21+ RRMM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11857154 | PMC |
| http://dx.doi.org/10.1159/000543347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effective and safe administration of Epcoritamab in relapsed CD19-CD5+ DLBCL following CAR-T therapy.
Blood Cell Ther
August 2025
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.
View Article and Find Full Text PDFAn Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Ann Hematol
September 2025
Hematology and Transplant Center, University Hospital"San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.
View Article and Find Full Text PDF[Immune-related colitis after immune checkpoint inhibitor rechallenging: a case report].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
Immune-related adverse events (irAE) are treatment-associated complications that single or multiple systems could be involved after immune checkpoint inhibitors(ICI), ranging from mild to life-threatening diseases, with significant heterogeneity. This is an important factor which might affect continuous ICI treatment. Patients who have experienced mild to moderate irAE could try ICI rechallenge after they recovered from irAE.
View Article and Find Full Text PDFIsatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702).
Blood
September 2025
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Isatuximab is an IgG1k monoclonal antibody that binds with high affinity to CD38 expressed on plasma cells. Anti-CD38 antibodies have shown efficacy as monotherapy and in combination in a variety of settings for patients with multiple myeloma and light chain (AL) amyloidosis. This multi-center, cooperative group phase 2 trial was designed to evaluate hematologic response, organ response, and safety of isatuximab monotherapy for the treatment of relapsed AL amyloidosis.
View Article and Find Full Text PDFComparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies.
Ann Hematol
September 2025
Excellence Center for Comprehensive Cancer (ECCCC), King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target for novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific T-cell engagers (BiTEs), which vary in efficacy, toxicity, and accessibility. To compare the efficacy and safety of BCMA-directed CAR-T therapies and BiTEs in R/R MM through a systematic review and meta-analysis.
View Article and Find Full Text PDF